The CombiGene® test from Procrea Fertility, genetic microarray analysis, offers couples with a family history of genetic anomalies and pregnant women, whose prenatal screening or prenatal ultrasound indicate a high risk of carrying a baby with genetic anomalies. The CombiGene® test allows the detection of very small genetic modifications not detected by previous conventional chromosomal analysis*. CombiGene® test has the ability to detect, simultaneously, over 150 anomalies including the following syndromes and conditions:

  • Angelman
  • DiGeorge
  • Miller-Diecker
  • Prader-Willi

When is the CombiGene® test used?

Prenatal Diagnosis*

  • Abnormal prenatal screening results

A family history of:

  • Chromosome abnormalities
  • Risk of a known genetic anomaly or mental retardation
  • Known inherited disorders

Abnormal fetal ultrasound signs:

  • Cardiac anomalies
  • Growth development delays in utero

Postnatal Diagnosis

  • Chromosome abnormalities (deletion, duplication)
  • Mental retardation of unknown etiology
  • Growth development delays

Speak with your physician to learn if the CombiGene® test is right for you.

*CCMG (Canadian College of Medical Geneticists) CCMG Guidelines for Genomic Microarray Testing June 2010

CombiGene® is a registered trademark of GROUPE OPMEDIC INC.


Autism Spectrum

Autism Spectrum Disorders or simply Autism (ASD) are characterized as the cause of significant social, communication and behavioral challenges. The defining characteristics of Autism and other related conditions in the autism spectrum includes, among others, lack of skills related to attention, memory, language, motor, behavior and social relationships.

Potential Benefits of Early Diagnosis

The earlier the diagnosis, the better the prognosis. As per Dr. Laurie Stephens from the Autism Spectrum Disorders Programs, the Help Group in California, “statistics show that between 25% and 50% of children receiving intense early intervention will increase their possibility to move into general education by kindergarten and many others will need significantly less service provision in future years”.

CombiGene® Test and ASD

The American College of Medical Genetics (ACMG) released in 2010, a new Practice Guideline that recommends chromosomal microarray analysis (CMA) as the first-line genetic test for all children with autism spectrum disorders and other developmental/intellectual disabilities or birth defects. The Canadian College of Medical Geneticists

(CCMG) has also released, in June 2010, similar recommendations.

To accelerate the diagnosis of ASD’s Procrea Fertility has developed the CombiGene®

Fragile X Syndrome

Fragile X syndrome is the most common inherited cause of mental retardation in children with ASD, affecting 1 in 4,000 boys and 1 in 9,000 girls. Procrea Fertility offers the test for Fragile X syndrome in combination with the CombiGene® test to optimize the diagnostic process.

CombiGene® is a registered trademark of GROUPE OPMEDIC INC.